

Correction to: Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel

This is a correction to: Bolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, Erika Hamilton, Nadia Harbeck, Jennifer Klemp, Michael Knauer, Sherko Kuemmel, Reshma Mahtani, Lee Schwartzberg, Cynthia Villarreal-Garza, Antonio Wolff, Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel, *The Oncologist*, 2022, oyac101, <https://doi.org/10.1093/oncolo/oyac101>

Financial disclosures for Reshma L. Mahtani were missing from the Conflict of Interest section of the originally published version of this article. The following disclosures were added before final publication:

Reshma L. Mahtani: Agendia, Amgen, AstraZeneca, Biotheranostics, Daiichi, Eisia, Genentech, Gilead, Lilly, Merck, Novartis, Pfizer, Puma, Sanofi, SeaGen (C/A)